On March 17, 2022 PokeAcell reported that it has initiated clinical testing of poke-101 in Melanoma in collaboration with National Center for Cancer Immune Therapy at Herlev Hospital and DTU Health Tech (Press release, PokeAcell, MAR 17, 2022, View Source [SID1234610218]). The trial will evaluate the safety and feasibility of treatment with PokeAcells ImmPACT cell product in Metastatic Melanoma and the first patients have received infusion in Q1 2022.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PokeAcells’ personalized cell product is produced for each individual patient and this trial offer a unique insight to the feasibility of patient specific manufacturing with the ImmPACT technology and safety of the treatment. Poke-101 is a multi-targeted T cell product made from T cells in patients own blood. The T cells are stimulated against a library of 30 shared melanoma antigens with PokeAcells proprietary ImmPACT technology.